Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

. Author manuscript; available in PMC: 2019 Oct 29.
Published in final edited form as: Clin Cancer Res. 2017 Sep 14;23(22):7047–7058. doi: 10.1158/1078-0432.CCR-17-0077

Figure 2. IFNβ boosts infiltration of CD8+ T cells post-tumor resection and has direct and indirect anti-tumor effects:

Figure 2.

(A) CD4+ and CD8+ T cells recruitment at 5 days post-tumor resection in response to mouse IFNβ. (B) (left) Fluorescence images of MSC-GFP and MSC-mIFNβ. Scale bar, 100 μm (right) Viability of CT2A and GL261 cells treated for 1, 3 and 5 days with CM of MSC-mIFNβ and MSC-GFP. (C) Representative flow cytometry density plots of cell cycle analysis and (D) immunocytochemical quantification of CT2A cells treated with mIFNβ CM for 72h and followed by a 1h BrdU pulse. BrdU positive nuclei (green)/ DAPI (blue). Scale bar, 100 μm (E) Comparison of Caspase 3/7 and 9 activity in CT2A-FmC cells cultured with mIFNβ CM for 1, 3 and 5 days. (F) Western blot analysis on CT2A cell lysates collected 6, 24, 48 and 72hrs after treatment with mIFNβ showing phosphorylation status of STAT1 (Tyr701), p38 (T189/Y182), and Akt (S473). (G) Scheme for testing efficacy of intratumoral MSC-mIFNβ or MSC-GFP in intact CT2A-FmC tumors in SCID (n=5 for MSC-GFP, n=4 for MSCmIFNβ) and C57/B6 mice (n=5 in each group). (H) Representative visible light plus superimposed bioluminescence images (BLI) of mice from each treatment group 16 days post-MSC implantation. (I) Plot of mean tumor growth following intratumoral MSC injections in C57/B6 mice. (J) Kaplan-Meier survival curves of C57/B6 or SCID mice bearing CT2A-FmC tumors intratumorally injected with MSC-mIFNβ or MSC-GFP.

HHS Vulnerability Disclosure